Seth Klarman
Baupost Group
Seth Klarman OREXIGEN THERAPEUTICS, INC COM stake
total: 272
Baupost Group OREXQ trades
- Total transactions:
- 5
- New positions:
- 1
- Sold out:
- 1
- Added:
- 2
- Reduced:
- 1
- Held since:
- 2015 Q3
- Held for:
- 11 quarters
- Latest activity:
- 2018 Q2
According to 2026 Q2 report, Seth Klarman doesn't hold any OREXIGEN THERAPEUTICS, INC COM (OREXQ) shares. To date, the estimated cost basis is nearly $0.69 for "buy" trades and estimated average "sell" price is $3.01. Baupost Group first purchased OREXQ in 2015 Q3, initially acquiring 821,363 shares. Since the initial investment in OREXIGEN THERAPEUTICS, INC COM (OREXQ), Baupost Group has made 4 more transactions.
When did Seth Klarman sell OREXIGEN THERAPEUTICS, INC COM (OREXQ)?
Seth Klarman sold off the entire OREXIGEN THERAPEUTICS, INC COM (OREXQ) position in 2018 Q2.
When did Seth Klarman buy OREXIGEN THERAPEUTICS, INC COM (OREXQ)?
Seth Klarman first invested in OREXIGEN THERAPEUTICS, INC COM (OREXQ) in 2015 Q3 at the reported quarter-end price of $1.86 per share.
What's the cost basis of Baupost Group's OREXQ stake?
The estimated cost basis for OREXIGEN THERAPEUTICS, INC COM (OREXQ) stake is around $0.69 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $0.69
- Weighted AVG sell price:
- $3.01
Seth Klarman's historical trades in OREXIGEN THERAPEUTICS, INC COM
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2018 Q2
|
0.00%
|
$0.21
|
-100% (-2,226,839)
|
|||
|
2016 Q3
|
0.11%
|
$3.32
|
-90.00% (-20,041,560)
|
|||
|
2016 Q1
|
0.18%
|
$0.56
|
+881.68% (+20,000,000)
|
|||
|
2015 Q4
|
0.07%
|
$1.72
|
+176.17% (+1,447,036)
|
|||
|
2015 Q3
|
0.03%
|
$1.86
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.